Notice Extra General Meeting in Ilya Pharma AB, May 13
Today there are >20 drug candidates that are genetically modified bacteria have been or are evaluated in clinical trials in a wide range of medical indications.
"Promoting healing of skin and mucosa by immunomodulation using CXCL12 producing lactic acid bacteria: From bench to bedside" by Industrial PhD student Emelie Öhnstedt.
Interested in learning more about Ilyas's ILP-technology, local-acting immunotherapies or any of the trials SITU-SAFE, SITU-SURGERY, SITU-HEAL or SITU-GUT or our recent work in AMR and meet our CEO Evelina Vågesjö, please reach out.